Tilray Brands (TLRY) Other Non-Current Assets (2017 - 2026)
Tilray Brands' (TLRY) quarterly Other Non-Current Assets came in at $11.0 million in Q2 2026, down 0.93% YoY from $11.1 million in Q2 2025, and down 0.84% on a QoQ basis from $11.1 million in Q1 2026.
Tilray Brands (TLRY) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Other Non-Current Assets data on file, last reported at $11.0 million in Q2 2026.
- Quarterly Other Non-Current Assets fell 0.93% year-over-year to $11.0 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $11.0 million (down 0.93% YoY) and the FY2026 annual result came in at $11.0 million, down 0.93% from the prior year.
- Other Non-Current Assets fell to $11.0 million in Q2 2026, from $11.1 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $11.7 million in Q3 2025 to a low of $222000.0 in Q2 2023.
- A 5-year average of $6.5 million and a median of $5.4 million in 2024 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 2825.0% in 2022, down 96.21% in 2022.
- Tracing TLRY's Other Non-Current Assets over 5 years: stood at $4.8 million in 2022, then surged by 96.08% to $9.4 million in 2023, then sank by 45.81% to $5.1 million in 2024, then soared by 117.25% to $11.1 million in 2025, then fell by 0.83% to $11.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $11.0 million (Q2 2026), $11.1 million (Q1 2026), and $11.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn | 10.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 10.98 Mn |
| Feb 28, 2026 | 11.07 Mn |
| Nov 30, 2025 | 11.07 Mn |
| Aug 31, 2025 | 11.66 Mn |
| May 31, 2025 | 11.08 Mn |
| Nov 30, 2024 | 5.10 Mn |
| Aug 31, 2024 | 5.34 Mn |
| May 31, 2024 | 5.40 Mn |
| Feb 29, 2024 | 5.61 Mn |
| Nov 30, 2023 | 9.41 Mn |
| Aug 31, 2023 | 8.65 Mn |
| May 31, 2023 | 222,000.00 |
| Feb 28, 2023 | 4.99 Mn |
| Nov 30, 2022 | 4.80 Mn |
| Aug 31, 2022 | 4.75 Mn |
| May 31, 2022 | 314,000.00 |
| Feb 28, 2022 | 314,000.00 |
| Nov 30, 2021 | 164,000.00 |
| Aug 31, 2021 | 198,000.00 |
| May 31, 2021 | 8.29 Mn |